					PRICES AND TRACEMENT OF COMMERCE		
Subs	titute for form 1449A/PTO			COMPLETE IF KNOWN			
INFORMATION DISCLOSUR			CLOSURE	Application Number	10/534,291		
PEC			DIICANT	Filing Date	May 9, 2005		
STATEMENT BY APPLICANT		PLICANI	First Named Inventor	Craig A. Coburn et al.			
	5.)			Group Art Unit	To Be Assigned 1626		
Hise as many sheets as necessary)			necessary)	Examiner Name	To Be Assigned YONG CHU		
OSH SET	1	of		Attorney Docket Number	21145YP		
	1 3 2006	PE STATEMENT BY	INFORMATION DIS PESTATEMENT BY AP 1 3 2006 By use as many sheets as recommended to the second sheet	INFORMATION DISCLOSURE PESTATEMENT BY APPLICANT 1 3 2006 In see as many sheets as necessary)	INFORMATION DISCLOSURE Application Number Filing Date First Named Inventor Group Art Unit Examiner Name		

		-		U.S. PA	ATENT DOCUMENTS	
Exai Initi	miner als*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
V	r	A	US 2003/0073217		Barr et al.	04/17/2003
		В	US 2003/0171291		Christie et al.	09/11/2003
		С	US 2001/0029563		Campanale et al.	10/11/2001
		D	6,117,639		Germann et al.	09/12/2000
		E.	5,986,102		Dolle, III et al.	11/16/1999
		F	5,847,109		Garti et al.	12/08/1998
	\Box	G	5,783,701		Tung et al.	07/21/1998
	\Box	Н	5,585,397		Tung et al.	12/17/1996
		I	6,482,832		Lubisch et al.	11/19/2002
		J	6,562,827		Lubisch et al.	05/13/2003
		K	6,753,327		Lubisch et al.	06/22/2004
		L	6,103,720		Lubisch et al.	08/15/2000
. V	K	M	5,780,498		Saika et al.	07/14/1998
- <u>`</u>						
						<u> </u>
			·			

	FOREIGN PATENT DOCUMENTS									
Exa	aminer	Cite	Foreign Patent Docu	ment Kind	Name of Patentee or Applicant	Date of Publication of Cited Document				
	Initials* No.		Office Number	Code (if known)	of Cited Document	MM-DD-YYYY				
ν	n	AA	CA 2,328,720		BASF AKTIENGESELLSCHAFT	10/28/1999				
/		BB	DE 198 18 614		BASF AG	10/21/1999				
		CC	DE 198 17 461		BASF AG	10/21/1999				
		DD	DE 196 50 975		BASF AG	06/10/1998				
		EE	WO 02/02518		Elan Pharmaceuticals, Inc.	01/10/2002				
		FF	WO 02/002518		Elan Pharmaceuticals, Inc.	01/10/2002				
		GG	WO 02/02505		Elan Pharmaceuticals, Inc.	01/10/2002				
		HH.	WO 01/70672		Elan Pharmaceuticals, Inc.	09/27/2001				
		II	WO 02/02506		Elan Pharmaceuticals, Inc.	01/10/2002				
1	K	IJ	WO 02/02520		Elan Pharmaceuticals, Inc.	01/10/2002				

Examiner Signature For Considered 1-23-2006

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

-	Substitute for form 1449A/PTO			COMPL IF KNOWN				
INFORMATION DISCLOSURE		Application Number	To Be Assigned 10/534291					
		A DDI ICA	NOT	Filing Date	May 9, 2005			
3	TATEMENT BY	APPLICA	YIN I	First Named Inventor	Coburn et al.			
				Group Art Unit	To Be Assigned 1626			
	(use as many sheets	s as necessary	<i>')</i>	Examiner Name	To Be Assigned YONG CHU			
Sheet	1	of	3	Attorney Docket Number	21145YP			

			U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
m	Α	US 6,562,783		Qiao et al.	05/13/2003
1	В	US 6,610,734		Kreft et al.	08/26/2003
7	С	US 6,660,741		Bornmann et al.	12/09/2003
n	D	US 6,706,742		DeNanteuil et al.	03/16/2004
-					
					•

				IGN PATENT D	OCUMENTS	
			Foreign Patent Docume	ent		Date of Publication of
Examiner Initials*	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY
						
			····			
		-				
				1		
Evenie		1/1/1			Date / -	
Examine Signatur	re re	1 Jone	-d_		Considered / -	-23-2006

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form * IDS Form* (IDS Folder), Merck & Co., Inc., 09/05/2003

Su	bstitute for form 1449A/PTO			COMPLETE IF KNOWN			
I	NFORMATION	N DIS	CLOSURE	Application Number	10/534,291		
0		37 A T		Filing Date	May 9, 2005		
2	STATEMENT BY APPLICANT			First Named Inventor	Craig A. Coburn et al.		
				Group Art Unit	To Be Assigned 1626		
	(use as many sheets as necessary)			Examiner Name	To Be Assigned YONG CHU		
eet	2	of	3	Attorney Docket Number	21145YP		

	U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.	U.S. Patent Docum		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY				
*,									

		FOREI	GN PATENT	T DOCUMENTS	
Cite No.	Office	Foreign Patent Documen Number	Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
KK	V	VO 02/002520		Elan Pharmaceuticals, Inc.	01/10/2002
LL	V	VO 96/22275		G.D. Searle & Co.	07/25/1996
	No.	No. Office	Foreign Patent Document No. Office Number	Foreign Patent Document	Cite No. Office Number Kind Code (if known) KK WO 02/002520 Elan Pharmaceuticals, Inc. LL WO 96/22275 G.D. Searle & Co.

Examiner Signature For Considered 1-23-2006

Approved for use through 7/31/2006. OMB 0651-0031 SUBSTITUTE for PTO/SB/084 (07-05). Information Disclosure Statement by Application Protection of Trademark Office 115 DEPARTMENT OF CAMAGENIA.

					Patent and Tradentals Off	ICE, U.S DEPARTMENT OF COMMERCE		
	Substitute for form 1449B/PTO			COMPLETE IF KNOWN				
	INFORMATIO		CLOSURE	Application Number	10/534,291			
	STATEMENT B	37 A D	DI ICANT	Filing Date	May 9, 2005			
	SIAIEMENIE) Ar	PLICANI	First Named Inventor	Craig A. Coburn	et al.		
			,	Group Art Unit	To Be Assigned	YONG CHU 1626		
	(use as many she	ets as n	secessary)	Examiner Name	To Be Assigned	YONG CHLS		
Shee	3	of	3	Attorney Docket Number	21145YP			

	NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.							
n	AAA	Moore et al., "Difluoro Ketone Peptidomimetics Suggest a Large S1 Pocket for Alzheimer's gamma-Secretase: Implications for Inhibitor Design," J. Med. Chem., Vol. 43, pp. 3434-3442 (2000)							
gr	ввв	Shearman et al., "L-685,458, an Aspartyl Protease Transition State Mimic, Is a Potent Inhibitor of Amyloid beta-Protein Precursor gamma-Secretase Activity," Biochemistry, Vol. 39, pp. 8698-8704 (2000)							
n	ccc	Li et al., "Photoactivated gamma-secretase inhibitors directed to the active site covalently label presentlin 1," Letter to Nature, Vol. 405, pp. 689-694 (2000)							
ye	DDD	Barrish et al., "Aminodiol HIV Protease Inhibitors. 1. Design, Synthesis, and Preliminary SAR;" J. Med. Chem., Vol. 37, pp. 1758-1768 (1994)							
'n									
-	_								
	L								

Examiner Signature York CL	Date Considered	1-23-2006